Compare Smith & Nephew plc (SNN) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Block Inc — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Block Inc trades at $77.24 (market cap $45.20B). The key difference: Block Inc is far larger — about 4.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Block Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Block Inc for 78 Days on average.
| SNN | XYZ | |
|---|---|---|
Market Cap | $11.10B | $45.20B |
Volume | 1,051,703 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $37.17 | $84.85 |
52-Week Low | $26.42 | $49.04 |
Typical Hold Time | 121 Days | 78 Days |
Enterprise Value | $14.13B | $40.10B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
XYZ trades at $75.21, down 1.13% on the day, with technical indicators showing bearish momentum near key support at $74. The company reported mixed Q3 2026 earnings with two beats and one miss, while revenue growth has slowed to 0.4% year-over-year in 2025. Analyst consensus remains strongly bullish with a $97.47 price target, representing 30% upside potential from current levels.
XYZ faces valuation concerns with a high P/E ratio of 134.34, though strong institutional support and expanding merchant partnerships provide growth catalysts. Key risks include declining net income margins and negative cash flow trends, requiring careful monitoring of upcoming Q3 2026 results for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
